[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiac-resynchronization-therapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiac-resynchronization-therapy":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,46,72,96,120,145,169,197],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100534655","csp-versus-bivp-for-heart-failure-patients-with-rvp-upgraded-to-cardiac-resynchronization-therapy-100534655",false,"NCT06241651","CSP Versus BiVP for Heart Failure Patients With RVP Upgraded to Cardiac Resynchronization Therapy","Conduction System Pacing Versus Biventricular Pacing for Heart Failure Patients With Right Ventricular Pacing Upgraded to Cardiac Resynchronization Therapy: a Prospective Multicenter Non-inferiority Randomized Controlled Study","CSP-UPGRADE","Inclusion Criteria:\n\n1. Patients with symptomatic heart failure (LVEF \\\u003C50%) after right ventricular pacing for at least 3 months;\n2. NYHA class II-IV;\n3. NT-proBNP \\>125pg\u002FmL in patients with sinus rhythm, NT-proBNP \\>250pg\u002FmL in patients with atrial fibrillation;\n4. Right ventricular pacing percentage \\>40%;\n5. Adult patients aged 18-80;\n6. With informed consent signed.\n\nExclusion Criteria:\n\n1. History of acute myocardial infarction within 3 months before enrollment;\n2. Frequent premature ventricular contraction (\\>15%) or malignant ventricular arrhythmia which is difficult to control;\n3. History of valvular heart disease intervention within 3 months before enrollment;\n4. After mechanical tricuspid valve replacement;\n5. Ventricular septal hypertrophy (≥15mm during diastole);\n6. Complex congenital heart disease;\n7. History of heart transplantation;\n8. Enrollment in any other study;\n9. Pregnant or with child-bearing plan;\n10. A life expectancy of less than 12 months.","ALL","18 Years","80 Years",{"count":21,"type":22},66,"ESTIMATED","INTERVENTIONAL",[25],"NA","The present study is a prospective, multicenter, non-inferiority, randomized controlled trail. It aims to investigate whether the efficacy of conduction system pacing (CSP) is non-inferior to biventricular pacing (BiVP) in patients with heart failure and right ventricular pacing (RVP) requiring upgrading to cardiac resynchronization therapy (CRT).",[28,29,30,31,32],"Conduction System Pacing","Biventricular Pacing","Cardiac Resynchronization Therapy","Right Ventricular Pacing","Heart Failure","RECRUITING","2026-05-11",{"date":36,"type":37},"2026-05-14","ACTUAL",{"date":39,"type":37},"2024-01-01",{"date":41,"type":22},"2027-03",{"name":43,"class":44},"The First Affiliated Hospital with Nanjing Medical University","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":45},"100524196","conduction-system-pacing-vs-biventricular-pacing-in-systolic-dysfunction-and-wide-qrs-mortality-heart-failure-hospitalization-or-cardiac-transplant-100524196","NCT06105580","Conduction System Pacing vs Biventricular Pacing in Systolic Dysfunction and Wide QRS: Mortality, Heart Failure Hospitalization or Cardiac Transplant","Conduction System Pacing vs Biventricular Resynchronization Therapy in Systolic Dysfunction and Wide QRS: Mortality, Heart Failure Hospitalization or Cardiac Transplant","CONSYST-CRT II","Inclusion Criteria:\n\n* Patient must indicate acceptance to participate in the study by signing an informed consent document.\n* Patient must be ≥ 18 years of age.\n* Left bundle branch block, QRS ≥130 and LVEF \\\u003C=35%. No indication of stimulation for AV block.\n* Non-left bundle branch block, QRS ≥150 and LVEF \\\u003C=35%.\n* Resynchronization therapy indication for ventricular dysfunction (LVEF \\\u003C40%) and indication of cardiac pacing for AV block.\n* LVEF \\\u003C=35% in NYHA class III or IV, atrial fibrillation and intrinsic QRS \\>=130 ms, provided a strategy to ensure biventricular capture is in place.\n\nExclusion Criteria:\n\n* Myocardial infarction, unstable angina or cardiac revascularization during the previous 3 months.\n* Pregnancy.\n* Participating currently in a clinical investigation that includes an active treatment.",{"count":55,"type":22},320,[25],"Conduction system pacing vs biventricular resynchronization therapy in systolic dysfunction and wide QRS: mortality, heart failure hospitalization or cardiac transplant (CONSYST-CRT II trial).\n\nSuperiority trial that aims to study the composite endpoint consisting of all-cause mortality, cardiac transplant or heart failure hospitalization at 12-month follow-up.",[30,32],[60,61,62],"left bundle branch pacing","biventricular pacing","cardiac resynchronization therapy","2026-03-30",{"date":65,"type":37},"2026-04-03",{"date":67,"type":37},"2023-11-27",{"date":69,"type":22},"2028-01",{"name":71,"class":44},"Hospital Clinic of Barcelona",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":79,"targetDuration":81,"studyType":82,"phases":4,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":45},"100624215","feasibility-and-outcomes-registry-of-lumenless-defibrillation-leads-for-conduction-system-pacing-100624215","NCT07406737","Feasibility and Outcomes Registry of Lumenless dEfibrillation Leads for Conduction System Pacing","FORGE CSP","Inclusion Criteria:\n\n* age \\> 18-year-old\n* indication for CRT according to current ESC\u002FEHRA guidelines\n* first-line LBBAP ICD lead implantation attempted\n* national insurance coverage\n\nExclusion Criteria:\n\n* pregnancy",{"count":80,"type":22},200,"12 Months","OBSERVATIONAL","The recent development and market introduction of small diameter implantable defibrillation leads able to deliver left bundle branch area pacing (LBBAP) has opened the possibility of achieving cardiac resynchronization therapy (CRT) using a single- or dual-chamber implantable-cardioverter defibrillator (ICD). This approach may reduce the number of intracardiac leads required and, consequently, has the potential to lower both procedural and long-term complication rates. However, the integration of these leads into currently recommended CRT strategies remains hypothetical. The FORGE CSP registry will prospectively enroll patients with an indication for CRT in whom implantation of a LBBAP ICD lead is attempted.",[30,85],"Left Bundle Branch Area Pacing","NOT_YET_RECRUITING","2026-02-06",{"date":89,"type":37},"2026-02-12",{"date":91,"type":22},"2026-05-01",{"date":93,"type":22},"2027-09-01",{"name":95,"class":44},"University Hospital, Caen",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":23,"phases":105,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":119},"100459661","his-bundle-corrective-pacing-in-heart-failure-100459661","NCT05265520","His-Bundle Corrective Pacing in Heart Failure","HIS-CRT","Inclusion Criteria:\n\n* Age 18 years or older (no upper age limit)\n* Optimal medical therapy for heart failure by current guidelines\n* Class IIa or IIb guideline-based indication for CRT-D implant in RBBB patients, including one of the following:\n\n  * New York Heart Association (NYHA) class II HF symptoms, LVEF ≤ 30% and QRS≥ 150 ms (IIb); OR\n  * NYHA class III-IV a HF, LVEF ≤ 35%, and QRS duration ≥ 150 ms (IIa); OR\n  * NYHA class III-IV a HF, LVEF ≤ 35%, and QRS duration 120-149 ms (IIb)\n\nExclusion Criteria:\n\n* Unable to obtain most recent imaging data from echocardiogram within 1 year prior to date of randomization\n* Left bundle branch block (LBBB) or intraventricular conduction delay (IVCD) ECG morphology\n* Unable or unwilling to follow study protocol\n* Less than 12 months life expectancy at consent\n* Pregnancy or planned pregnancy during duration of the study\n* On heart transplant list or likely to undergo heart transplant",{"count":104,"type":22},120,[25],"The investigators aim to prospectively evaluate the efficacy and mechanism of benefit of His-bundle pacing enhanced cardiac resynchronization therapy (His-CRT) vs. cardiac resynchronization therapy (BIV-CRT) in patients with heart failure and right bundle branch block (RBBB).",[108,32,109,30],"Right Bundle-Branch Block","His-bundle Pacing","2026-02-04",{"date":112,"type":37},"2026-02-09",{"date":114,"type":37},"2022-12-02",{"date":116,"type":22},"2028-07-01",{"name":118,"class":44},"University of Rochester",14,{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":82,"phases":4,"briefSummary":129,"conditions":130,"keywords":133,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":45},"100482642","absolute-coronary-flow-in-patients-with-heart-failure-with-reduced-ejection-fraction-and-left-bundle-branch-block-with-cardiac-resynchronization-therapy-100482642","NCT05564689","Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy","FLOW-LBBB","Inclusion Criteria:\n\n* Age \\> 18\n* QRS ≥ 150 ms before implantation\n* Heart failure because of dilated cardiomypathy\n* Sinus rhythm\n* Stable medical therapy\n* LBBB\n* CRT device\n\nExclusion Criteria:\n\n* eGFR \\\u003C 30 ml\u002Fmin\n* Severe valvular heart disease\n* Permanent atrial fibrillation or atrial flutter\n* Prior PCI or CABG\n* Prior myocardial infarction\n* Heart failure due to ischemic heart disease\n* Other type of device (pacemaker, ICD)\n* Not able to give informed consent\n* Does not understand Danish",{"count":128,"type":22},60,"Cardiac resynchronization therapy (CRT) is an effective therapeutic strategy in patients with symptomatic heart failure (HF) patients with LVEF of ≤35% and left bundle branch block (LBBB). However, approximately one-third of CRT-recipients do not improve after therapy (non-responders), despite meeting the required criteria.\n\nPrevious studies have documented that the positive respons to CRT is related to the delayed electrical activation of the left ventricle in patients with LBBB. It has also been illustrated that non-ischemic CRT-candidates with LBBB demonstrate lower regional myocardial blood flow and metabolism in the septum. Additionally, it has been suggested that LBBB can lead to impaired coronary blood flow in the left anterior descending artery (LAD). This observation is based on an echocardiography-based study, that showed that the percentage of diastolic flow duration (%DD) in LAD was shorter in patients with LBBB compared to the control-group and patients with right-ventricular pacing.\n\nIt has been demonstrated that CRT has positive effects on septal myocardial perfusion in patients with HF and LBBB. The dominant hypothesis explaining this phenomenon is built on improved septal myocardial work after CRT-implantation, which leads to increased myocardial energy and therefore increased myocardial perfusion. In contrast, it has been suggested that due to re-established synchronous left ventricular electrical activation, CRT reduces the septal intramyocardial pressure in early diastole, leading to a relatively longer antegrade flow duration in LAD. Therefore, the aim of the study is to evaluate the effect of CRT on coronary blood flow in LAD in patients with non-ischemic HF and LBBB.\n\nThe investigators hypothesize that increased LV-function after CRT not only is due to resynchronized LV ejection and filling, but also improved coronary flow.\n\nThe study aims to enroll 60 patients with heart failure due to non-ischemic dilated cardiomyopathy, LBBB, with or without CRT. All patients meeting the criteria will be recruited from the outpatient clinic at the Department of Cardiology, Aalborg University Hospital.\n\nInvasive flow measurements in the LAD, including fractional flow reserve (FFR), absolute coronary flow and -reserve will be conducted with the CRT on and off, respectively.",[131,32,30,132],"Left Bundle-Branch Block","Dilated Cardiomyopathy",[134,135],"absolute coronary flow","fractional flow reserve","2025-06-16",{"date":138,"type":37},"2025-06-18",{"date":140,"type":37},"2022-09-29",{"date":142,"type":22},"2026-09-30",{"name":144,"class":44},"Ashkan Eftekhari",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":23,"phases":154,"briefSummary":155,"conditions":156,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":168},"100550958","safety-and-performance-evaluation-of-a-new-catheter-range-for-lead-implantation-at-interventricular-septum-100550958","NCT06453850","Safety and Performance Evaluation of a New Catheter Range for Lead Implantation At Interventricular Septum","POLARIS","Inclusion criteria (phase I):\n\n* Patient indicated for cardiac pacing according to the most recent guidelines from the European Society of Cardiology (ESC)\n* Patient planned for a de novo implantation of any Single Chamber (SR) or Dual Chamber (DR) CE marked pacemaker\n* Patient planned for a catheter-guided implantation in the interventricular septum area\n* Patient planned for the implantation of any CE marked ventricular pacing lead compatible with the FLEXIGO delivery catheter\n* Patient reviewed, signed and dated the Informed Consent Form (ICF)\n\nInclusion criteria (phase II):\n\n* Patient indicated for cardiac pacing or CRT according to the most recent guidelines from the ESC\n* Patient planned for a de novo implantation of any SR or DR CE marked pacemaker, or any CE marked CRT-D\n* Patient planned for a catheter-guided implantation in the interventricular septum area\n* Patient planned for the implantation of any CE marked ventricular pacing lead compatible with the FLEXIGO delivery catheter\n* Patient reviewed, signed and dated the ICF\n\nExclusion criteria (phase I):\n\n* Patient planned for a device upgrade, or a device or a lead replacement\n* Patient with a congenital heart disease\n* Patient with significant hypertrophic cardiomyopathy, cardiac amyloidosis or obstructive hypertrophic cardiomyopathy\n* Patient with a Left Ventricular Ejection Fraction (LVEF) ≤ 35%\n* Patient already enrolled in another clinical investigation that could confound the results of this clinical investigation (e.g., clinical investigations involving intra-cardiac device)\n* Patient implanted despite a contraindication for cardiac pacing system implantation (i.e. patient implanted with a defibrillator, patient contraindicated for a single dose of 310 μg of dexamethasone sodium phosphate, patient implanted with a tricuspid replacement heart valve, with prior tricuspid valve intervention or with a significant tricuspid valve disease that may lead to future replacement heart valve surgery)\n* Minor age patient (i.e. under 18 years of age)\n* Incapacitated patient, under guardianship, kept in detention, refusing to cooperate or not able to understand the purpose of this clinical investigation\n* Non-menopausal women\n\nExclusion criteria (phase II):\n\n* Patient planned for a device upgrade, or a device or a lead replacement\n* Patient with a congenital heart disease\n* Patient with significant hypertrophic cardiomyopathy, cardiac amyloidosis or obstructive hypertrophic cardiomyopathy\n* Patient already enrolled in another clinical investigation that could confound the results of this clinical investigation (e.g., clinical investigations involving intra-cardiac device)\n* Patient implanted despite a contraindication for cardiac pacing system implantation (i.e. patient implanted with a defibrillator, patient contraindicated for a single dose of 310 μg of dexamethasone sodium phosphate, patient implanted with a tricuspid replacement heart valve, with prior tricuspid valve intervention or with a significant tricuspid valve disease that may lead to future replacement heart valve surgery)\n* Minor age patient (i.e. under 18 years of age)\n* Incapacitated patient, under guardianship, kept in detention, refusing to cooperate or not able to understand the purpose of this clinical investigation\n* Non-menopausal women",{"count":153,"type":22},216,[25],"The purpose of the clinical investigation is to evaluate the safety of the FLEXIGO delivery catheter for transvenous pacing lead implantation.",[157,30,85],"Bradycardia","2025-03-03",{"date":160,"type":37},"2025-03-06",{"date":162,"type":37},"2025-02-14",{"date":164,"type":22},"2026-12",{"name":166,"class":167},"MicroPort CRM","INDUSTRY",3,{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":175,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":17,"minAge":177,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":23,"phases":180,"briefSummary":181,"conditions":182,"keywords":185,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":45},"100513880","verifying-remote-monitoring-effect-on-net-cardiovascular-outcome-remoteverify-rve-100513880","NCT05971225","Verifying Remote Monitoring Effect on Net Cardiovascular Outcome; RemoteVerify (RêVe)","Prospective Multicenter Observation Study on the Association Between Remote Monitoring and Clinical Outcome in Heart Failure Patients (Verifying Remote Monitoring Effect on Net Cardiovascular Outcome; RemoteVerify (RêVe))","ReVe","Inclusion Criteria:\n\n* consented heart failure patients (LVEF\\\u003C=40%) with Biotronik wireless monitoring capable ICD\u002FCRTs aged \\>20 years\n* patients who are new to remote monitoring\n\nExclusion Criteria:\n\n* For patients with a life expectancy of less than 6 months. If patient do not understand the contents of wireless monitoring or it is difficult to fill out the consent form due to cognitive decline.\n\nIf wireless monitoring is performed with a patient enrolled in another clinical trial which remote monitoring may affect the previous enrolled study.","20 Years",{"count":179,"type":22},450,[25],"This study investigates the impact and safety of wireless monitoring on the prognosis of heart failure patients with implanted pacemakers and defibrillators. It aims to examine the frequency of unplanned early hospital visits and the early diagnosis\u002Fintervention of disease exacerbation based on the presence or absence of wireless monitoring. Additionally, the study analyzes the influence of wireless monitoring on the patient's disease progression as well as satisfaction of the study participants.",[183,184,30],"Congestive Heart Failure","Defibrillators",[186,187,184,62],"remote monitoring","congestive heart failure","2024-11-28",{"date":190,"type":37},"2024-12-03",{"date":192,"type":37},"2023-11-11",{"date":194,"type":22},"2027-04-30",{"name":196,"class":44},"Saint Vincent's Hospital, Korea",{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":203,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":205,"targetDuration":4,"studyType":23,"phases":207,"briefSummary":208,"conditions":209,"keywords":211,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":223},"100464389","cardiac-resynchronization-therapy-delivery-guided-non-invasive-electrical-and-venous-anatomy-assessment-100464389","NCT05327062","Cardiac Resynchronization Therapy Delivery Guided Non-Invasive Electrical and Venous Anatomy Assessment","CRT-DRIVE: Cardiac Resynchronization Therapy Delivery Guided Non-Invasive Electrical and Venous Anatomy Assessment","CRT-DRIVE","Eligible subjects shall meet all following criteria:\n\n* Appropriately signed and dated informed consent.\n* Age ≥18 years at time of consent.\n* CRT indication according to the 2021 ESC guidelines on cardiac pacing and CRT (class I and IIA indication in patients with LBBB QRS morphology) or to 2017 AHA\u002FACC\u002FHFSA guidelines (COR I).\n* Sinus rhythm\n* QRS duration ≥130 ms\n* Left bundle branch block\n* Left ventricular ejection fraction ≤35%\n* Symptomatic heart failure NYHA class ≥ II\n* Documented stable medical treatment for at least 6 months\n* No cardiovascular intervention during the last 6 month\n\nExclusion Criteria are:\n\n* History of persistent or permanent atrial fibrillation\n* Previous pacemaker or ICD implantation\n* Indication to pacing due to bradycardia\n* Patients considered for His bundle pacing or cardiac conduction pacing\n* Patients with unstable angina\n* Subject experienced a recent myocardial infarction, within 40 days prior to enrollment\n* Subject underwent coronary artery bypass graft or valve surgery, within 90 days prior to enrollment\n* Subject is post heart transplantation, or is actively listed on the transplantation list, or has reasonable probability (per investigator's discretion) of undergoing transplantation in the next year\n* Subject is implanted with a left ventricular assist device\n* Subject is on continuous or uninterrupted infusion (inotropic) therapy for heart failure\n* Subject has severe aortic stenosis (with a valve area of \\\u003C1.0 cm2 or significant valve disease expected to be operated within study period)\n* Subject has congenital heart disease\n* Subject has a mechanical right-sided heart valve\n* Subject has a life expectancy of less than one year in the opinion of the investigator\n* Pregnant or breastfeeding women, or women of child bearing potential and who are not on a reliable form of birth control\n* Subject is enrolled in one or more concurrent studies that would confound the results of this study\n* Patients who have contraindications to CT scanning.\n* Patients with chronic kidney diseases and estimated glomerular filtration rate (eGMR) calculated based on CKD-EPI 2009 \\\u003C 40 ml\u002Fmin\u002F1.73m2",{"count":206,"type":22},150,[25],"The objective of this prospective, multicenter controlled study is to assess the feasibility of a patient-tailored implantation by creating a cloud-based pre-procedural multimodality CRT-roadmap by integration of 3D images from 3D activation sequence from ECG, and coronary venous anatomy from cardiac computed tomography. This CRT-roadmap will be used to guide LV lead placement to a coronary vein in an electrically late-activated region.\n\nStudy Hypothesis: At least 75% of patients undergoing a CRT implantation guided by non-invasive electrical and venous anatomy assessment (XSPLINE technology) will show a reduction of left ventricular end-systolic volume of 15% or more at 6-month evaluation.",[30,210,131],"Chronic Heart Failure",[212,213],"Non-invasive activation mapping","Coronary Sinus","2024-10-22",{"date":216,"type":37},"2024-10-24",{"date":218,"type":37},"2023-03-06",{"date":220,"type":22},"2025-09",{"name":222,"class":167},"XSpline S.p.A.",13]